Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Payables (2016 - 2025)

Alterity Therapeutics has reported Payables over the past 5 years, most recently at $1.2 million for Q2 2019.

  • For Q2 2019, Payables fell 23.74% year-over-year to $1.2 million; the TTM value through Jun 2019 reached $1.2 million, down 23.74%, while the annual FY2019 figure was $1.2 million, 23.74% down from the prior year.
  • Payables for Q2 2019 was $1.2 million at Alterity Therapeutics, up from $1916.2 in the prior quarter.
  • Over five years, Payables peaked at $1.6 million in Q4 2016 and troughed at $670.38 in Q2 2017.
  • A 5-year average of $728667.1 and a median of $945765.9 in 2017 define the central range for Payables.
  • On a YoY basis, Payables climbed as much as 231991.89% in 2018 and fell as far as 99.8% in 2018.
  • Year by year, Payables stood at $1.3 million in 2015, then increased by 24.81% to $1.6 million in 2016, then crashed by 40.52% to $945765.9 in 2017, then tumbled by 99.8% to $1916.2 in 2018, then soared by 61819.22% to $1.2 million in 2019.
  • Business Quant data shows Payables for ATHE at $1.2 million in Q2 2019, $1916.2 in Q4 2018, and $1.6 million in Q2 2018.